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Key Points
• We elucidate a molecular
mechanism by which thyroid
hormones sustain TCL
survival.
• We demonstrate that the
membrane receptor of THs,
integrin avb3, constitutes
a potential target for TCL.
The interaction of lymphoid tumor cells with components of the extracellular matrix via
integrinavb3 allows tumor survival andgrowth. This integrinwasdemonstrated to be the
membrane receptor for thyroid hormones (THs) in several tissues. We found that THs,
acting as soluble integrin avb3 ligands, activated growth-related signaling pathways in
T-cell lymphomas (TCLs). Specifically, TH-activated avb3 integrin signaling promoted
TCL proliferation and angiogenesis, in part, via the upregulation of vascular endothelial
growth factor (VEGF). Consequently, genetic or pharmacologic inhibition of integrin avb3
decreased VEGF production and induced TCL cell death in vitro and in human xenograft
models. In sum,weshowthat integrinavb3 transducesprosurvival signals intoTCLnuclei,
suggesting a novel mechanism for the endocrine modulation of TCL pathophysiology.
Targeting this mechanism could constitute an effective and potentially low-toxicity
chemotherapy-free treatment of TCL patients. (Blood. 2015;125(5):841-851)
Introduction
T-cell lymphomas (TCLs) are a molecular and clinical heterogeneous
group of lymphoproliferative disorders broadly classified according
to their origin into T-cell lymphoblastic lymphoma (from precursor
T cells) and peripheral TCLs (PTCL) (frommature T cells).1 Among
the later, the most common varieties are the nodal types, including
PTCL not otherwise specified (PTCL-NOS), anaplastic large-cell
lymphoma (ALCL), and angioimmunoblastic TCL (AITL). Although
some subtypes may follow a more benign prolonged course, the vast
majority of PTCL patients have poor prognoses due to the com-
bination of an aggressive clinical course and the lack of specific
treatments originally designed for B-cell lymphomas.2-4
The cellular microenvironment plays an essential role in the patho-
genesis and progression of lymphomas.5,6 The interaction of lymphoma
cells with ligand molecules in the extracellular matrix (ECM) is respon-
sible for the colonization of specific anatomical sites as well as for
lymphoma-cell survival and aggressiveness.6 The principal ECM re-
ceptors are integrins that mediate cell attachment to other cells
and the ECM. Engagement of integrins by ECM ligands induces
a variety of intracellular signals that regulate migration, differentiation,
proliferation, and apoptosis. Altered integrin expression or signaling is
frequently associated with lymphoma-cell invasion and growth.7
Integrins are a/b heterodimers with different ligand specificity.
Integrin avb3, expressed in malignant cells, osteoclasts, and dividing
endothelial andvascular smoothmuscle cells,8 bindsECMcomponents
(eg, vitronectin) and is also the membrane receptor for thyroid hor-
mones (THs).9-11 Therefore, THs exert their biological actions through
simultaneous binding of nuclear receptors and integrin avb3. TH-
induced activation of integrin avb3 triggers a signaling cascade that
modulates the transcription of a set of genes that will complement the
nuclear-initiated program.10-12 We recently demonstrated that physi-
ological levels of THs can stimulate the proliferation of murine TCLs
through complementary intracellular pathways involving nuclear and
membrane receptors, ultimately leading to protein kinase C, extracel-
lular signal-regulated kinase 1/2 (ERK1/2), and nuclear factor kB
(NF-kB) activation.13,14 In this context, a hypothyroid state would be
beneficial for TCL patients; however, this strategy is associated with
potentially harmful effects that preclude its clinical application. We
hypothesized that targeting integrin avb3 could help to overcome this
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limitation; however, the mechanistic contributions of integrin avb3
to human TCL survival are unknown.
Herein, we characterize the role of TH-induced integrin avb3
activation in the survival of malignant T cells. We determine the sig-
naling and transcriptional program triggered by TH binding to integrin
avb3 on TCLs leading to increase proliferation and angiogenesis. We
also demonstrate that targeting integrin avb3 is sufficient to induce
lymphoma regression in vivo.
Methods
TCL cell lines and primary samples
Jurkat and CUTLL1 immature TCL/leukemia cells were obtained from Dr
Roxana Schillaci (Instituto de Biologı́a y Medicina Experimental, CONICET,
Argentina) and Dr Adolfo Ferrando (Columbia University, New York, NY),
respectively; MJ, HuT78, and Mac2A were obtained from the American Type
Culture Collection; Karpas299 and SUDHL1 were obtained from the DMSZ;
and OCI-Ly12 and OCI-Ly13.2 were obtained from the Ontario Cancer
Institute, Canada. Cells were cultured in RPMI 1640 medium, supplemented
with 10% fetal bovine serum, 2mMglutamine, and antibiotics (from Invitrogen).
We conducted monthly tests forMycoplasma sp. and other contaminants
and quarterly cell identification by single-nucleotide polymorphism.
Primary samples were obtained from the Weill Cornell Medical College
Biobank under institutional review board approval 0107004999A006.
Tissue culture treatments
Cell lines were treated at different times with free or agarose-bound hormones
at physiological concentration (T3 or T3-AG5 1 nM; T4 or T4-AG5 100 nM;
Sigma-Aldrich). For [3H]-TdR incorporation and migration assays, cells were
synchronized by 12-hour serum starvation (in RPMI) as published previously.13
For all other experimental procedures, cells were cultured 24 hours before
treatments in RPMI with 10% TH–depleted serum (Sunny-Laboratory).
Human TCL xenograft models
Experiments involving animals were approved by the Institutional Animal Care
and Use Committee of Weill Cornell Medical College. For human cell line
xenografts, female andmale severe combined immunodeficiency (SCID) (NOD.
CB17-Prkdcscid/J) mice 6 to 10 weeks old were obtained from Taconic Farms.
A cohort of mice was subcutaneously injected in the left flank with 2 3 107
CUTLL1 cells previously transfected with small interfering RNA (siRNA)
against ITGAV, ITGB3, or noncoding sequence. Another cohort of mice was
subcutaneously injected in the leftflankwith 107OCI-Ly12cells. Tumorvolume
was measured every other day for the duration of the experiment, and the area
under the tumor growth curve (AUC) was calculated. When OCI-Ly12 xeno-
grafts reached a palpable size (;75 to 100 mm3), mice were randomized into
2 treatment arms to receive vehicle (35% PEG300, 5% Tween-80, and 65%
dextrose 5% in water) or cilengitide (125 mg/kg per day, MedKoo) by intra-
peritoneal injection. For patient-derived xenografts, previously established
patient-derived tumorgrafts (1mm3blocks)were subcutaneously expanded into
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice 6 to 8 weeks old obtained
from our own colony. Tumor assessment and treatments were done as before.
Mice from both models were weighed every other day and killed by cervical
dislocation under anesthesia when at least 20% of tumors reached 20 mm in
any dimension. At the end of the experiment, tumor and other tissues were
harvested, weighed, and macroscopically examined for signs of tissue damage.
Statistical analysis
Means of the different experimental groups were analyzed for statistical sig-
nificance with the software GraphPad PRISM 4.0 (GraphPad Software), using
unpaired2-tailedStudent t test or 2-wayanalysisofvariance followedbyTukey’s
analysis. Differences between means were considered significant if P , .05.
Results are expressed as mean6 standard error of the mean (SEM). Correlation
results from patient samples were analyzed using Pearson test for sampled
Gaussian populations (2 tailed) and Spearman test for nonparametric corre-
lation (VEGFA vs ITGAV in ALCL patients samples).
Additional methods are described in supplemental Materials and methods
(available on the BloodWeb site).
Results
TCLs express canonical and noncanonical TH receptors
Wedemonstrated that THs inducemurineTCLproliferation in vitro13,14
by activating both nuclear and membrane receptors. To determine
whether THs also contribute to maintaining proliferation in human
malignant T cells, we first characterized the expression of nuclear
TRa and TRb, and the putative membrane integrin avb3 receptors,
in a panel of TCL cell lines. This panel included immature TCL/
leukemia (Jurkat and CUTLL1) and mature TCLs comprising the
cutaneous TCL cell lines MJ and HuT78, the PTCL-NOS cell line
OCI-Ly12, the ALCL anaplastic lymphoma kinase (ALK)-negative
cell lines OCI-Ly13.2 and Mac2a, and the ALCL ALK-positive cell
lines Karpas299 and SUDHL1. All these cells expressed THRA,
ITGAV, and ITGB3 (Figure 1A), but not THRB, at similar or higher
levels than normal peripheral and tonsillar T cells. TH receptors were
also expressed at the protein level as shown for representative cell
lines (Figure 1B). This suggests that integrins and nuclear TH re-
ceptors are functional to normal and malignant T cells.
Activation of nuclear and membrane TH receptors induces
proliferation of TCLs
Wedetermined the functionalityofTH receptors by exposingCUTLL1
cells to physiological concentrations of free and agarose-coupled (cell-
impermeable) T3 and T4. Agarose-bound THs bind exclusively to the
membrane receptor without binding to nuclear receptors,9 providing
a discriminatory tool to activate exclusively integrin avb3. We found
that free and TH-AGhormones significantly increased the proliferation
of CUTLL1 cells (Figure 1C). A higher effect was obtained by the
combination at physiological dose and ratio of both T3 and T4 or
T3-AG and T4-AG compared with each hormone alone (Figure 1C).
A similar proliferative effect was found across immature and mature
TCL cell lines that showed an increase in proliferative activity ranging
from 30% to 50% (Figure 1D).
To further characterize this effect, we measured DNA synthesis
and expressionofmolecularmarkersof cell-cycleprogression in repre-
sentative immature (CUTLL1) and mature (HuT78 and OCI-Ly12)
cells.We found that THandTH-AG significantly increasedDNAsyn-
thesis (Figure 1E). This was associated with a cell-cycle progression–
dependent induction of cyclins upon hormone addition to arrested
cells. An initial increase of D-type cyclins, required for the progression
from G0 to G1, was followed by subsequent increase in cyclin E2
(G1 to S and S phase) and cyclin B1 (G2 to M) in CUTLL1 cells
exposed to either TH or TH-AG (Figure 1F). A similar pattern for
cyclins of theD andE familieswas found inHut78 andOCI-Ly12 cells
(Figure 1G and supplemental Figure 1A). These effects were also
linked to hormone-mediated upregulation of proliferating cell nuclear
antigen (PCNA) levels, a central component in DNA synthesis and
replication (Figure 1H and supplemental Figure 1B). No induction of
apoptosis was found when TCL cells were cultured in the presence or
absence of THs (supplemental Figure 1C). Taken together, these data
suggest that THs acting through membrane and nuclear receptors
constitute proliferative signals for TCLs.
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Figure 1. THs mediate proliferative effects in TCL cell lines. (A) mRNA levels of ITGAV, ITGB3, and THRA in a panel of TCL cell lines in comparison with mRNA levels in
normal T cells. Results shown are the mean 6 SEM of n 5 3 independent experiments. (B) Protein levels of integrin avb3 and TRab obtained by flow cytometry in CUTLL1,
SUDHL1, OCI-Ly12, and HuT 78 cell lines. Results are representative of n 5 3 experiments. (C) CUTLL1 cells treated for 24 hours with free or agarose-bound T3 (1 nM) and
T4 (100 nM) or a combination of the same concentrations of both free (TH) or AG-coupled (TH-AG) hormones were evaluated by Cell Titer Blue assay. Results shown
represent the percent of proliferative cells respective to CT. (D) Cell proliferation after 24-hour treatment with TH or TH-AG compared with CT (dashed line) in the complete
TCL cell line panel. (E) Evaluation of DNA synthesis by [3H]TdR incorporation of CUTLL1, HuT 78, and OCI-Ly12 cells after 24 hours of hormone treatment vs CT. (F) Cyclin
mRNA expression levels in CUTLL1 cells by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) after 2-, 6-, 12-, and 18-hour treatment with TH-AG
(right) and free TH (left) compared with CT. (G) Cyclin D1 mRNA expression levels in HuT 78 and OCI-Ly12 cells by qRT-PCR after a 2-, 6-, and 12-hour treatment with
TH-AG and free TH compared with CT. (H) PCNA protein levels by flow cytometry in CUTLL1 cells (right) and mRNA (left) levels in CUTLL1, HuT 78, and OCI-Ly12 cells after
24-hour treatment with free TH and AG-bound TH compared with CT. qRT-PCR results shown are the mean 6 SEM of at least n 5 3 independent experiments. For PCNA
protein levels, a representative of 4 experiments is displayed. CT, control.
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TH-activated integrin avb3 dimer sustains TCL proliferation
Physiological levels of THs increase the proliferation of TCLs
through membrane and nuclear receptors. However, targeting
integrin avb3, instead of TH production or the ubiquitous THRA,
would constitute a more feasible anti-lymphoma strategy to trans-
late to patients. The TH binding site on integrin avb3 is in close
proximity to the Arg-Gly-Asp (RGD) recognition site9,11; accord-
ingly, a competing RGD peptide completely abrogated the effect of
TH-AG on cell proliferation and decreased a significant fraction
of the prosurvival effect of free TH (Figure 2A). In the absence of
integrin avb3 ligand, the RGD peptide alone had no effect on cell
proliferation (Figure 2A). To further validate integrin avb3 tar-
geting as a therapeutic strategy in TCL, we transfected CUTLL1
cells with siRNA to integrin av (si-ITGAV) and/or integrin b3 (si-
ITGB3) and evaluated THs effect on these conditions vs non-
targeting sequence siRNA (si-CT) as control. After 24 and 48 hours,
si-ITGAV and si-ITGB3 effectively and selectively (vs other RGD
integrins expressed inTCLs) knocked down integrinavb3 (Figure 2B
and supplemental Figure 2A-B). Both si-ITGAV and si-ITGB3
decreased CUTLL1 cell growth in presence of TH (Figure 2C), sug-
gesting that the heterodimer is necessary for the proliferative effect of
TH on TCLs. DNA synthesis analysis demonstrated that, although
si-ITGAV, si-ITGB3, and si-ITGAV1si-ITGB3 did not significantly
affectCUTLL1proliferation in the absenceofavb3 ligand,TH-induced
proliferation was completely abrogated (Figure 2D). No differences
were observed when both si-ITGAV and si-ITGB3 were used in com-
bination, indicating that downregulation of any of the components
impaired the activity of the integrin heterodimer (Figure 2D). The effect
of si-ITGAV and si-ITGB3 (vs si-CT) in the mature TCL HuT78 and
OCI-Ly12 cells was similar to that with CUTLL1 cells (Figure 2E-F
and supplemental Figure 2B), suggesting that theavb3 dimer is critical
for TH-induced proliferation in most T-cell malignances.
TH activates the integrin avb3 dimer in the presence of
ECM ligands
To evaluate the magnitude of TH activity on integrin avb3–mediated
proliferation in the presence of its ECM ligand, we cultured TCL cells
in the presence of vitronectin. Vitronectin alone had a tendency to
increase lymphoma cell proliferation, but to a lesser extent than that
observed with THs (Figure 2G). When added together, vitronectin
did not compete out the TH effect, and for HuT78 cells, the com-
bination of vitronectin and TH provided a greater proliferative effect
than each ligand alone (Figure 2G).
To deeper determine whether the presence of cellular and non-
cellular stromal components influences the activation of integrin avb3
by TH, as well as the antiproliferative effect of integrinavb3 targeting,
we developed a tridimensional culture system that mimics cellular
and noncellular components of ECM in mature TCLs. We adapted a
hydrogel system15,16 by combining functionalized polyethylene glycol
with a crosslinker peptide containing an integrinavb3 binding site and
a collagenase degradable sequence. As inert stromal cellular compo-
nent, we used irradiated human tonsil–derived HK follicular den-
dritic cells (supplemental Figure 3). OCI-Ly12 cells were grown in this
culture system in presence and absence of physiological levels of TH
and in presence and absence of the specific RGD peptidomimetic
integrin avb3 inhibitor cilengitide.17 We measured cell proliferation
and clustering by microscopic examination. In these artificial ECM
conditions, OCI-Ly12 proliferated between 2 and 3 times more than
in regular tissue culture conditions (data not shown). Moreover, in
the presence of physiological levels of TH, clustering and proliferation
increased (Figure 2H), suggesting that both RGD stromal components
andTHcooperate towardTCLproliferation in conditions that resemble
the natural microenvironment of these tumors. Conversely, cilengitide
abrogated the clustering and proliferative effect of the artificial ECM
and the THs (Figure 2H).
TH-activated integrin avb3 regulates prosurvival
transcriptional programs
To determine the mechanism by which TH-activated avb3 integrins
maintain the proliferation of TCLs, we analyzed transcriptional
changes induced byTH-AG(vs agarose alone asCT) inCUTLL1 cells
by RNA sequencing.We identified 118 upregulated and 5 downregu-
lated transcripts (Figure 3A and supplemental Table 1) involved in
“translation” (eg, RPL13, RPL27A, RPL36), “respiratory chain” (eg,
NUDFB1/2, NDUFA13, UQCR11), “angiogenesis” (eg, VEGFB),
“lymphocyte proliferation/differentiation,” and “DNA replication/
transcription” (eg, DBP, IL4, EDF1, DOK2) (Figure 3A-B).
Previously, we identified ERK1/2 and NF-kB as effectors of TH-
activated avb3 integrins in murine TCLs.14 Pathway analysis of
these TH-AG–mobilized genes also suggested an association with
ERK1/2 and NF-kB (Figure 3B). We therefore validated the up-
regulation of genes presenting consensus NF-kB binding sites in their
promoter region (ie, DBP, VEGFB, IL4, and DOK2) in independent
biological experiments. We found that TH-activated avb3 integrin
signaling upregulated these genes in CUTLL1 cells and in the mature
HuT78 and OCI-Ly12 cell lines (Figure 3C). To determine whether
free THs could bypass the integrin receptor in upregulating target
genes, we analyzed the upregulation of IL-4 and VEGFB by free THs
in the presence and absence of integrinavb3.We found that CUTLL1
transfected with either si-ITGAV or si-ITGB3 (vs si-CT) failed
to upregulate IL-4 and VEGFB expression upon TH stimulation
(Figure 3D).Thesedata indicate that TH-dependent regulationof these
genes is due to the activation of avb3 and further inhibition of this
integrin abrogates this signaling event.
Pathway analysis and our previous findings in murine TCL
models14 suggest that NF-kB mediates downstream of the TH-
activated avb3 integrin signaling. We now confirm that in human
TCLs, TH also induced the activation and therefore nuclear trans-
location of NF-kB (Figure 3E). Moreover, administration of the
specific NF-kB inhibitor BAY-11-7082 significantly abrogated
the upregulation of VEGFB and IL4 on both immature (CUTLL1)
andmature (HuT78 andOCI-Ly12) TCL cell lines (Figure 3F). BAY-
11-7082 alonewas unable to decreaseVEGFBor IL4 (Figure 3E). This
suggests that NF-kB is downstream of TH-activated avb3 integrin
signaling and regulates the transcription of genes involved in pro-
liferation and angiogenesis.
TH-activated integrin avb3 induces VEGF expression
and activity
VEGF expression and angiogenesis correlate with survival and pro-
gnosis in PTCL-NOS and AITL patients.18-20 VEGFB is a member of
a larger family of growth factors that also includes VEGFA, VEGFC,
VEGFD, and PLGF.21 In addition to VEGFB, the only member ex-
pressed in samples of a series of TCL patients (74 PTCL-NOS, 30
ALCL-ALK positive, 24 ALCL-ALK negative, and 41 AITL) was
VEGFA (supplemental Figure 4A). Therefore, we analyzed whether
VEGFA, like VEGFB, was under the control of integrin avb3 in
TCL.We transfectedCUTTL1 cellswith either si-ITGAVor si-ITGB3
(vs si-CT) followed by TH stimulation. Similar to IL-4 and VEGFB,
VEGFAwasupregulated uponTHstimulation, exclusively incellswith
intact integrin avb3 dimer (supplemental Figure 4B), indicating that




 http://ashpublications.org/blood/article-pdf/125/5/841/1388573/841.pdf by guest on 24 N
ovem
ber 2021
this member is also part of the integrin avb3–dependent VEGF family
in TCLs. Moreover, NF-kB inhibition using BAY-11-7082 abrogated
this effect (supplemental Figure 4C). To determine whether this as-
sociation was present in our series of TCL patients, we analyzed the
expressionofTHRA, ITGAV, and ITGB3 (supplemental Figure 5A-C)
and the correlation betweenVEGFA andVEGFBvs ITGAV and ITGB3
(supplemental Figure 5D). We observed a statistically significant pos-
itive correlation between ITGAV and ITGB3withVEGFB andVEGFA
Figure 2. Integrin avb3 is the membrane receptor for THs in human TCL. (A) Blockade of the TH-mediated proliferative effect by 1 nM RGD peptide, added 10 minutes before
24-hour hormone treatment, was analyzed by Cell Titer Blue assay. (B) CUTLL1 cells were transfected by electroporation with siRNA against ITGAV (si-ITGAV), ITGB3 (si-ITGB3), or
noncoding siRNA as control (si-CT). mRNA levels of target genes were analyzed by qRT-PCR 24 and 48 hours posttransfection. (C) Effect of ITGAV and ITGB3 knockdown on CUTLL1
cell growth by Trypan Blue staining. (D-F) Knockdown of ITGAV and/or ITGB3 abrogates the TH proliferative effect as measured by [3H]TdR incorporation (D) and cell proliferation by
Cell Titer Blue assay (E) after 24 hours of TH treatment in CUTLL1 cells. Similar results were found in mature TCL, HuT 78, and OCI.Ly12 cells (F). (G) Effect of 250 ng/mL vitronectin
ligand and/ or THs on cell proliferation in CUTLL1, HuT 78, and OCI-Ly12 cells measured by [3H]TdR incorporation after 24-hour treatment. (H) Growth of OCI-Ly12 cells cultured in
an artificial ECM system that offers an RGD ligand, in the presence or absence of physiological levels of TH and in the presence or absence of the inhibitor of integrin avb3
cilengitide. Cell proliferation and clustering was measured by microscopical examination. Representative photographs (scale bar, 100 mm) of 4 replicate experiments are shown.
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in almost all of the TCL subtypes (Figure 4A and supplemental
Figure 5D), suggesting a functional association in primary lesions.
VEGFA and VEGFB may contribute to TCL proliferation by 2
mechanisms: one involving the expression of VEGF receptors in TCL
cells (autocrine),22,23 and another due to sustained angiogenesis through
a paracrine effect on the tumor microenvironment.21 Therefore, a
TH-dependent increase ofVEGFAand/orVEGFBmaypromoteTCL
growthby inducingproliferation of themalignant populationaswell as
Figure 3. THs acting at the membrane receptor initiate a transcriptional program. (A) A graphical heatmap representation of changes (log2 fold change) in gene
expression of CUTLL1 cells after treatment with TH-AG vs CT (AG alone); n5 3 independent samples for each condition. Selected Gene Ontology categories for upregulated
genes are shown on the right. (B) The top network identified by Ingenuity Pathway Analysis on mobilized genes by AG-bound hormones treated cells vs CT. (C) Validation of
a select number of genes from the network shown in panel B, 24 hours posttreatment with TH-AG in immature CUTLL1 cells and mature TCL cell lines, HuT 78, and OCI-
Ly12. (D) Regulation of IL-4 and VEGFBmRNA levels after 2 hours of treatment with free TH in the presence and absence of integrin avb3. (E) NF-kB localization by confocal
microscopy of CUTLL1 cells treated or not (Control) with THs for 15 minutes. Representative photographs (scale bar, 20 mm). (F) Effect of 1 mM of NFkB inhibitor, BAY 11-
7082, on TH-mediated regulation of IL-4 and VEGFB genes in CUTLL1, HuT 78, and OCI-Ly12 cells.
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by promoting angiogenesis. To determine the extent of this effect, we
first analyzedwhether TH-AG could increase the expression ofVEGFB
and VEGFA in our panel of malignant T cells. Similarly to CUTLL1,
TH-AG increased VEGFB messenger RNA (mRNA) levels in Jurkat,
HuT-78, OCI-Ly12, and Karpas299 and increased VEGFA in Jurkat,
HuT78,MJ, andOCI-Ly12 cells (Figure 4B). This effectwas dependent
Figure 4. THs contribute to TCL malignant phenotype through angiogenesis induction. (A) Pearson correlation between ITGAV and ITGB3 with VEGFB and VEGFA
levels in TCL patients. (B) mRNA levels of VEGFA and VEGFB in the panel of immature and mature TCLs after 24-hour treatment with TH-AG compared with CT. (C) Transcript
abundance of VEGFA (right) and VEGFB (left) was evaluated in CUTLL1, HuT78, and OCI-Ly12 cell lines transfected for 48 hours with siRNA against ITGAV (si-ITGAV), ITGB3
(si-ITGB3), or noncoding sequence (si-CT) and then treated for 24 hours with TH-AG or agarose alone (as CT). (D) Transcript abundance of VEGFB (right) and VEGFA (left) was
evaluated in CUTLL1, HuT78, and OCI-Ly12 cell lines after 24-hour treatment with 250 ng/mL vitronectin (VN). (E) Induction of HMEC1 cell migration by conditioned medium from
CUTLL1 cells treated or not with TH-AG. Representative photographs (scale bar, 60 mm) of the endothelial cells that migrate through the chamber membrane in the presence of CT
or conditioned medium. (F) Quantitation of HMEC1 cell migration by conditioned medium from CUTLL, HuT 78, and OCI-Ly12 cells treated or not with TH-AG and preincubated
with the anti-VEGF bevacizumab (10 mg/mL) vs vehicle. (G) Cell migration quantitation of HMEC1 cells in the presence or absence of conditioned medium from si-RNA–transfected
CUTLL1 cells treated with TH-AG vs CT for 24 hours. Mean 6 SEM of at least 3 independent experiments are shown.
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on integrin avb3, because siRNA to ITGAV or ITGB3 completely ab-
rogated TH-AG–induced upregulation of VEGFB and VEGFA ex-
pression in CUTLL1, HuT-78, and OCI-Ly12 cells (Figure 4C),
suggesting that inmostTCLs, the expressionofVEGFligandsdepends
on the TH-avb3 integrin axis activity. Moreover, these effects were
not induced by the ECM integrinavb3 ligand vitronectin (Figure 4D).
To further characterize the paracrine consequences of TH-induced
integrin-dependent VEGF upregulation, we analyzed the effect of a
conditionedmedium fromCUTLL1,HuT78, orOCI-Ly12cells treated
with TH-AG on the migration of endothelial cells, a VEGF-dependent
effect. Conditioned mediumwas placed in the lower compartment of a
dual-chamber device separated from the upper compartment containing
HMEC1 endothelial cells by a polycarbonate porous membrane. We
then quantified the HMEC1 endothelial cells that migrated to the lower
compartment and found a significant increase in the number of endo-
thelial cells that migrated to the lower compartment when TH-
AG–treated TCL conditioned media was used (Figure 4E-F). To
confirm that this effect was VEGF dependent, we conducted this
experiment adding the anti-VEGF antibody bevacizumab to HMEC1
culture medium. We found that anti-VEGF effectively impaired
the HMEC1 migration effect of the conditioned media (Figure 4F).
Bevacizumab had a negligible effect on the migration of endothelial
cells culture with control media (Figure 4F). This suggests that VEGF
upregulation leads to a fully functional ligand. Furthermore, this effect
was completely abrogated when the conditioned medium was obtained
from CUTLL1 cells transfected with siRNA to ITGAV or ITGB3 and
treatedwithTH-AGfor24hours (Figure4GandsupplementalFigure6).
VEGF mediates TH-induced TCL proliferation
To analyze the possible role of TH-induced VEGF in an autocrine
circuit, we first determined the effect of recombinant VEGF on the
proliferation of TCL cells. We found that recombinant VEGF induced
a significant increase in the proliferation ofCUTLL1,HuT78, andOCI-
Ly12 cells (Figure 5A).We then evaluated the effect of the anti-VEGF
antibody, bevacizumab, and of a specific inhibitor of VEGFR, axitinib,
on the proliferative action of TH on these cell lines. Both bevacizumab
and axitinib abrogated the proliferation induced by THs in both
Figure 5. Autocrine effect of TH-induced VEGF in TCL proliferation. (A) TCL proliferation after 24-hour treatment with recombinant VEGF vs CT. (B) DNA synthesis
measured by [3H]TdR incorporation in CUTLL1, HuT 78, and OCI-Ly12 cells exposed to TH and treated with the anti-VEGF bevacizumab or vehicle and the VEGFR inhibitor
axitinib or vehicle. Results shown are the mean6 SEM of independent triplicates. (C) CUTLL1 cells were transfected with si-ITGAV, si-ITGB3, or si-CT and injected into SCID
mice (n 5 4 for each treatment). Tumor growth from day 4 to 15 after implantation was measured by the AUC. (D) Levels of VEGFA and active caspase-3 by immu-
nohistochemistry staining in tissue sections of the tumors obtained from panel A. Representative photographs are shown (scale bar, 50 mm). (E) Representative photographs
of CD31 staining of tissue sections from the CUTLL1 tumors. Quantification of the blood vessel area (lumen) from the CUTLL1 tumors (right).
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immature andmatureTCLcells (Figure 5B), thus indicating thatVEGF
andVEGFR contribute to the TH-induced proliferation of TCL cells.
We characterized the functional consequences of integrin avb3 in-
hibition in vivo in a TCL xenograft model of CUTLL1 cells transfected
with si-CT, si-ITGAV, or si-ITGB3. CUTLL1 transfected with either
si-ITGAV or si-ITGB3 developed smaller tumors than si-CT–
transfected cells (Figure 5C). TCL xenografts from si-ITGAV–
or si-ITGB3–transfected cells showed a marked decrease in VEGFA
and increase in activated caspase-3 (Figure 5D and supplemental
Figure 7). Additionally, CD31 immunostaining of the tumor vas-
culature revealed an anatomically defective vascularization in
these lymphomas (Figure 5E). TCLs from si-ITGAV and si-ITGB3
CUTLL1 cells showed blood vessels with a smaller lumen area
(si-ITGAV5 0.406 0.123 1023; si-ITGB35 0.346 0.083 1023
vs si-CT 5 1.07 6 0.25 3 1023 mm2, P , .01), suggesting a di-
minished angiogenic potential in tumors from cells with either in-
tegrin aV or b3 knockdown. Taken together, these results indicate
that THs induce integrin avb3–dependent production of fully func-
tional VEGFs with autocrine and paracrine effects.
Inhibition of integrin avb3 decreases the proliferation of TCL
in vivo
To determine whether this pathway can be therapeutically capitalized
upon for the treatment of TCL patients, we assessed the effect of
cilengitide, a selective avb3 integrin inhibitor currently in clinical
use.17We developed a PTCL-NOSmodel by xenografting OCI-Ly12
cells into SCIDmice. Once OCI-Ly12 tumors reached a palpable size,
we treated them with cilengitide at a dose equivalent to half of the
maximum tolerated dose inhumanpatients or vehicle.At the endof the
treatment, cilengitide-treatedmice showed significantly smaller tumors
compared with vehicle-treated CTs (P, .001; Figure 6A). This effect
was associated with decreased activation of the NF-kB pathway
(Figure 6B), decreasedmicrovascular lumen size (0.446 0.223 1023
vs 0.976 0.553 1023 mm2, vehicle vs cilengitide, respectively,
P , .05; Figure 6C, upper) and increased apoptosis (7.36 3.5% vs
12.06 4.2%, vehicle vs cilengitide, respectively,P, .05; Figure 6C
lower). There was no toxicity associated with this treatment as deter-
mined by body weight and macroscopic examination of mouse tissue.
To determine the effect of cilengitide in TCLs that more closely
resemble the patients’ lymphoma heterogeneity and are less manipu-
lated than cells kept in culture, we developed 2 models of patient-
derived xenografts. We xenografted ALCL ALK-negative passage 2
lymphomas and ALCLALK-positive passage 4 lymphomas into NSG
mice. Once these tumors reached a palpable size, we treated them with
cilengitide or vehicle as before. At the end of the treatment, cilengitide-
treated mice showed significantly smaller tumors compared with
vehicle-treated CTs (P 5 .0159 and P 5 .0104 for ALCL ALK
negative and ALCL ALK positive, respectively; Figure 6D-E).
Figure 6. Pharmacologic inhibition of integrin shows
anti-lymphoma effect in PTCL-NOS and ALCL mouse
models. (A) Tumor volume (measured by AUC, from
day 1 to day 20) in OCI-Ly12 xenografted mice treated
with vehicle vs cilengitide. (B) DNA-binding capacity of
NF-kB family members assessed by an enzyme-linked
immunosorbent assay–based assay in extracted nu-
clear fractions of disaggregated lymphoma tissues
from the tumors obtained in panel A. (C) Microvascu-
lar lumen (by intravascular isolectin) and apoptotic
bodies (by terminal deoxynucleotidyltransferase-
mediated dUTP nick end labeling assay) in representa-
tive tissue sections of the tumors from vehicle- and
cilengitide-treated OCI-Ly12 mice. Scale bar, 25 mm
(upper) and 100 mm (lower). The white lines show
representative maximum lumen size measurements.
(D-E) AUC of tumor growth of ALCL ALK-negative (D)
and ALCL ALK-positive (E) patient-derived lympho-
mas in NSG mice treated with vehicle vs cilengitide. (F)
Cartoon representation of TH regulation of TCL prosur-
vival pathways via the activation of avb3 integrins.
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There was no toxicity associated with this treatment as determined
by body weight and macroscopic examination of mouse tissue.
Discussion
Here,we show that physiological concentrations ofTHs acting through
integrin avb3 induce angiogenesis and proliferation of immature
and mature TCL cells. We characterized the transcriptional pro-
gram triggered upon activation of the integrin avb3 by TH that
is ultimately linked to the induction of angiogenic and cell pro-
liferation genes such as VEGF, an NF-kB–dependent mechanism
(Figure 6F). Moreover, we found that pharmacologic inhibition of
integrin avb3 reduces the proliferation of TCLs in preclinical
models (Figure 6F), including patient-derived xenografts of ALCL
tumors.
Integrin avb3 is the receptor for ECM proteins including
vitronectin, Cyr61, osteopontin, fibronectin, and fibrinogen as well as
for soluble factors like THs. TH also binds 1 or more isoforms of a
nuclear receptor, TR. Both TH receptors, TRa and the integrin avb3,
were expressed in TCL cells and patient samples, indicating that they
are potentially sensitive to the circulating levels of T3 andT4 normally
present in the tumor microenvironment. Moreover, recent data
suggested that TCL cells could have an enriched TH micro-
environment by a mechanism that involves epigenetic transcriptional
control of DIO3 (type III deiodinase). This enzyme plays an essential
role in regulating TH inactivation in tissues, and it was found
hypermethylated and repressed in malignant T cells.24 Transcript
analysis of our TCL panel showed undetectable levels of DIO3 and
DIO2 and low expression of DIO1 (not shown). Nonetheless, using
physiological levels of T3 and T4, we demonstrated that THs are
growth factors for TCL. These effects were mediated by free and
cell-impermeable hormones and included increments in cell pro-
liferation, metabolism, and cell-cycle induction and progression.
In the characterization of the programs induced by TH on
integrin avb3, we found genes related to signaling cascades for
proliferation and angiogenesis, such as IL-4, DOK2, and VEGFB,
that present NF-kBbinding sites in their promoter regions.We further
confirmed the participation of NF-kB in the signaling cascade
triggered upon integrin avb3 activation. IL-4 is a proliferative
cytokine for PTCL25 and T-cell acute lymphoblastic leukemia cells, in
the later through a mammalian target of rapamycin–dependent reg-
ulation of cell-cycle progression.26 The adaptor DOK2, frequently
overexpressed in ALCL,27 acts as a common substrate for multiple
tyrosine kinases and induces cell migration, in part, by interacting
with integrin b3.28 Possibly the most therapeutically actionable
finding is theavb3-dependent upregulation ofVEGFBandVEGFA.
Malignant T cells produce and express VEGF receptors, thus
supporting autocrine and paracrine VEGF-mediated pathways in
lymphangiogenesis.22,23 VEGF and VEGF receptors are expressed
in vascular and lymphomacells ofAILTandPTCL-NOSpatients.20,22,23
Moreover, the expression of VEGF was associated with tumor
staging, bone marrow invasion, and prognosis in PTCL-NOS
patients.19We found that TH-dependentavb3-activation increased
VEGFB and VEGFA expression and secretion, which in turn ac-
tivated endothelial cell migration as well as immature and mature
TCL proliferation, establishing an autocrine effect. Conversely,
anti-VEGF antibody treatment impaired TH-induced endothelial
cell migration and lymphoma proliferation.
The proliferative action of THs was abrogated by knockdown
of aV and/or b3 integrins and by an integrin avb3–selective
RGD peptidomimetic compound, thus indicating that the hetero-
dimeric integrin avb3 is sufficient to transduce the proliferative
effects of THs. Engagement of integrin avb3 by the ECM ligand
vitronectin did not decrease the TH effect of proliferation. More-
over, in organoid models of TCL, simultaneous activation of
integrin avb3 by RGD-containing ligands and TH resulted in
increased proliferation and clustering. Subsequent exposure of
these organoids to the integrin avb3 inhibitor cilengitide29,30
decreased the proliferation and clustering effect. Furthermore,
cilengitide showed anti-lymphoma effect in cell-line–derived and
patient-derived xenograft models of mature TCLs. Targeting the
integrin avb3 in TCL and patient-derived xenografts, by either a
genomic or a pharmacologic approach, significantly reduced tumor
growth, an effect partially mediated by defective angiogenesis.
This could represent a potential strategy to test in the clinical
setting, because cilengitide is currently being tested in phase 2/3
clinical trials for solid tumors.30 In this regard, our finding that
integrin avb3 mediates proliferation and survival of TCL would
make it an attractive target for therapy, alone or in combination with
conventional schedules.
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